Correlation of Serum IGF-1 and sFlt-1 Levels with Adverse Pregnancy Outcomes in Patients with Severe Preeclampsia.

OBJECTIVE

Our aim is to analyze the association of serum insulin-like growth factor 1 (IGF-1) and soluble fms-like tyrosine kinase 1 (sFlt-1) levels with adverse pregnancy outcomes in patients with severe preeclampsia (SPE).

METHODS

A total of 108 patients with SPE who received treatment in Tianjin Medical University General Hospital in China from January 2017 to December 2019 were selected for the study. According to the presence or lack of presence of adverse pregnancy outcomes, the patients were divided into the occurrence group (n = 34) and the nonoccurrence group (n = 74). Before treatment, patient serum vitamin A (VA), vitamin E (VE), IGF-1 and sFlt-1 levels were measured. Logistic regression analysis was performed for the correlation of serum IGF-1 and sFlt-1 with adverse pregnancy outcomes in patients with severe SPE. In addition, a Receiver Operator Characteristic (ROC) curve was plotted to test the prediction value of patient serum VA, VE, IGF-1 and sFlt-1 levels.

RESULTS

Compared with the nonoccurrence group, patients in the occurrence group had much lower serum VA, VE and IGF-1 levels and significantly higher sFlt-1 levels. Logistic regression analysis revealed that serum levels of VA, VE, IGF-1 and sFlt-1 before treatment were associated with adverse pregnancy outcomes in patients with SPE, and the ROC curve proved the accuracy of serum VA, VE, IGF-1 and sFlt-1 levels in predicting adverse pregnancy outcomes in patients with SPE.

CONCLUSION

Abnormal expression of serum IGF-1 and sFlt-1 before treatment in patients with SPE is correlated with adverse pregnancy outcomes. Clinically, the risk for adverse pregnancy outcomes can be predicted and intervention instituted by detecting pretreatment serum IGF-1 and sFlt-1 expression in patients with SPE.